Literature DB >> 12368073

Statins as anti-inflammatory agents.

Gabriele Weitz-Schmidt1.   

Abstract

The beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in cardiovascular disease have generally been attributed to their cholesterol-lowering property. However, an increasing number of in vitro and in vivo studies indicate that statins have direct anti-inflammatory effects that are not mediated by their hypocholesterolemic activity. In this article, the HMG-CoA-reductase-dependent and -independent mechanisms by which statins might affect leukocyte adhesion and migration to sites of inflammation are reviewed and the implications for the design of new statin-derived drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368073     DOI: 10.1016/s0165-6147(02)02077-1

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  82 in total

1.  Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models.

Authors:  Mahesh M Ghaisas; Prasad R Dandawate; Suyash A Zawar; Yogesh S Ahire; Santosh P Gandhi
Journal:  Inflammopharmacology       Date:  2010-06-08       Impact factor: 4.473

2.  Pharmacotherapy in the treatment of Alzheimer's disease: an update.

Authors:  Brian E Leonard
Journal:  World Psychiatry       Date:  2004-06       Impact factor: 49.548

Review 3.  Maintenance of radiation-induced intestinal fibrosis: cellular and molecular features.

Authors:  Valérie Haydont; Marie-Catherine Vozenin-Brotons
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

Review 4.  Myeloid cells in atherosclerosis: initiators and decision shapers.

Authors:  Oliver Soehnlein; Christian Weber
Journal:  Semin Immunopathol       Date:  2009-02-24       Impact factor: 9.623

5.  A statin-based inhibitor of lymphocyte function antigen-1 protects against ischemia/reperfusion-induced leukocyte adhesion in the colon.

Authors:  Min Xiu Wan; Rene Schramm; Daniel Klintman; Karl Welzenbach; Gabriele Weitz-Schmidt; Henrik Thorlacius
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 6.  Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.

Authors:  William Nseir; Mahmud Mahamid
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

7.  Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals.

Authors:  Alexandre B Rosendo; Luciana O Lima; Felipe Dal-Pizzol; Silvana Almeida
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

8.  Novel simvastatin inhalation formulation and characterisation.

Authors:  Alaa S Tulbah; Hui Xin Ong; Paolo Colombo; Paul M Young; Daniela Traini
Journal:  AAPS PharmSciTech       Date:  2014-05-08       Impact factor: 3.246

9.  High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART).

Authors:  Mitchell S V Elkind; Ralph L Sacco; Robert B Macarthur; Ellinor Peerschke; Greg Neils; Howard Andrews; Joshua Stillman; Tania Corporan; Dana Leifer; Rui Liu; Ken Cheung
Journal:  Cerebrovasc Dis       Date:  2009-07-16       Impact factor: 2.762

Review 10.  The cardioprotective effects of statins.

Authors:  Jean Davignon
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.